CTLA4 and cancer: Inhibition of the two best described immune checkpoints, CTLA-4 and PD-1, using monoclonal antibodies has led to a breakthrough in cancer immunotherapy in the recent decade, showing remarkable responses and improved overall survival (OS) in many different solid tumors (24–27).